专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011084433A3 AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES 审中-公开
标题翻译： AZA桥环熔融吲哚和吲哚
公开(公告)号：WO2011084433A3
公开(公告)日：2011-11-10
申请号：PCT/US2010060343
申请日：2010-12-14
申请人： ABBOTT LAB , SHI LEI , BUNNELLE WILLIAM H , LI TAO , SCANIO MARC J , SCHRIMPF MICHAEL R , LEE CHIH-HUNG
发明人： SHI LEI , BUNNELLE WILLIAM H , LI TAO , SCANIO MARC J , SCHRIMPF MICHAEL R , LEE CHIH-HUNG
IPC分类号： C07D471/18 , A61K31/407 , A61K31/439 , A61P25/18 , A61P25/28 , C07D487/18
CPC分类号： C07D471/18 , A61K31/439 , A61K31/4439 , A61K31/4709 , C07D487/08
摘要： The present application relates to indole and indoline derivatives of formula (I) wherein a, R1, R2, R3, h, i, j, m, n, L, Q, and X are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions.
摘要翻译：本申请涉及式（I）的吲哚和吲哚啉衍生物，其中a，R1，R2，R3，h，i，j，m，n，L，Q和X如说明书中所定义。本申请还涉及包含此类化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法。

2. 发明申请

WO2010138828A3 POTASSIUM CHANNEL MODULATORS 审中-公开
标题翻译：钾通道调节器
公开(公告)号：WO2010138828A3
公开(公告)日：2011-02-17
申请号：PCT/US2010036596
申请日：2010-05-28
申请人： ABBOTT LAB , SCANIO MARC J , BUNNELLE WILLIAM H , CARROLL WILLIAM A , PEDDI SRIDHAR , PEREZ-MEDRANO ARTURO , SHI LEI
发明人： SCANIO MARC J , BUNNELLE WILLIAM H , CARROLL WILLIAM A , PEDDI SRIDHAR , PEREZ-MEDRANO ARTURO , SHI LEI
IPC分类号： C07D239/92 , A61K31/517 , A61K31/519 , A61P25/00 , C07D405/12 , C07D495/04
CPC分类号： C07D239/92 , C07D405/12 , C07D495/04
摘要： Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G1, X, R1, and R2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
摘要翻译：本文公开了式（I）的KCNQ钾通道调节剂，其中环G1，X，R1和R2如说明书中所定义。包含这些化合物的组合物; 还描述了使用这些化合物和组合物治疗病症和病症的方法。

3. 发明专利

IL256851D0 Substituted tricyclics and method of use 未知
公开(公告)号：IL256851D0
公开(公告)日：2018-03-29
申请号：IL25685118
申请日：2018-01-11
申请人： GALAPAGOS NV , ABBVIE SARL , ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
发明人： ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
IPC分类号： C07D20060101
摘要： wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

4. 发明专利

IL274112D0 Substituted tricyclics and method of use 未知
公开(公告)号：IL274112D0
公开(公告)日：2020-06-30
申请号：IL27411220
申请日：2020-04-21
申请人： GALAPAGOS NV , ABBVIE SARL , ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
发明人： ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
IPC分类号： A61K31/357 , A61K31/397 , A61K31/433 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/5377 , A61K45/06 , A61P11/00 , A61P43/00
摘要： wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

5. 发明专利

IL256851A Substituted tricyclics and method of use 未知
公开(公告)号：IL256851A
公开(公告)日：2020-05-31
申请号：IL25685118
申请日：2018-01-11
申请人： GALAPAGOS NV , ABBVIE SARL , ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
发明人： ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
IPC分类号： A61K31/397 , A61K31/357 , A61K31/433 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/5377 , A61K45/06 , A61P11/00
摘要： wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

6. 发明专利

IL285433D0 Substituted tricyclics and method of use 未知
公开(公告)号：IL285433D0
公开(公告)日：2021-09-30
申请号：IL28543321
申请日：2021-08-08
申请人： GALAPAGOS NV , ABBVIE SARL , ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
发明人： ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
IPC分类号： A61K31/357 , A61K31/397 , A61K31/433 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/5377 , A61K45/06 , A61P11/00 , A61P43/00
摘要： wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

7. 发明专利

IL274112A Substituted tricyclics and method of use 未知
公开(公告)号：IL274112A
公开(公告)日：2021-08-31
申请号：IL27411220
申请日：2020-04-21
申请人： GALAPAGOS NV , ABBVIE SARL , ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
发明人： ALTENBACH ROBERT J , BOGDAN ANDREW , COWART MARLON D , ESMIEU WILLIAM RAMESH , GFESSER GREGORY A , GRESZLER STEPHEN N , KOENIG JOHN R , KYM PHILIP R , LIU BO , MALAGU KARINE FABIENNE , PATEL SACHIN V , SCANIO MARC J , SEARLE XENIA B , VOIGHT ERIC , WANG XUEQING , YEUNG MING C
IPC分类号： A61K31/357 , A61K31/397 , A61K31/433 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/5377 , A61K45/06 , A61P11/00 , A61P43/00
摘要： wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

8. 发明专利

MX2012007031A INDOLES E INDOLINAS FUSIONADAS AL ANILLO AMINA DE CABEZA DE PUENTE UTILES PARA TRATAR TRANSTORNOS NEURODEGENERATIVOS Y NEUROPSIQUIATRICOS. 未知
公开(公告)号：MX2012007031A
公开(公告)日：2012-07-04
申请号：MX2012007031
申请日：2010-12-14
申请人： ABBOTT LAB
发明人： BUNNELLE WILLIAM H , SHI LEI , LEE CHIH-HUNG , SCHRIMPF MICHAEL R , LI TAO , SCANIO MARC J
IPC分类号： A61K31/407 , C07D471/18 , A61P25/28 , C07D487/18
摘要： La presente solicitud se refiere a derivados de indol e indolina de la fórmula (I), fórmula (ii), fórmula (III), o fórmula (IV), en donde a, R2, R3, h, k, m, n, L, Q, X, y Z son como se define en la especificación. La presente solicitud también se refiere a composiciones que comprenden dichos compuestos, y sus medicamentos para tratar trastornos de neurodegeneración y neuropsiquiátricos. (Ver Formula) .

9. 发明专利

CA2782361C BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS 未知
公开(公告)号：CA2782361C
公开(公告)日：2018-01-16
申请号：CA2782361
申请日：2010-12-14
申请人： ABBOTT LAB
发明人： SHI LEI , BUNNELLE WILLIAM H , LI TAO , SCANIO MARC J , SCHRIMPF MICHAEL R , LEE CHIH-HUNG
IPC分类号： C07D471/18 , A61K31/407 , A61P25/28 , C07D487/18
摘要： The present application relates to indole and indoline derivatives of formula (I), formula (II), formula (III), or formula (IV) wherein a, R2, R3, h, k, m, n, L, Q, X, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and their medicaments for treating neurodegeneration and neuropsychiatric disorders.

10. 发明专利

ES2378116T3 Derivados acetamida y carboxamida de azaadamantano y métodos de uso de los mismos 未知
公开(公告)号：ES2378116T3
公开(公告)日：2012-04-09
申请号：ES08732554
申请日：2008-03-20
申请人： ABBOTT LAB
发明人： SCANIO MARC J , SHI LEI , BUNNELLE WILLIAM , SCHRIMPF MICHAEL
IPC分类号： C07D471/18 , A61K31/439 , A61P25/00
摘要： Un compuesto de fórmula (I) en la que Y1 es o A es arilo, heteroarilo, heterociclo, cicloalquilo, cicloalquenilo, arilalquilo, heteroarilalquilo, heterocicloalquilo, cicloalquilalquilo, o cicloalquenilalquilo en la que cada uno del arilo, heteroarilo, heterociclo, cicloalquilo, cicloalquenilo, el resto arilo de arilalquilo, el resto heteroarilo del heteroarilalquilo, el resto heterociclo del heterocicloalquilo, el resto cicloalquilo del cicloalquilalquilo, y el resto cicloalquenilo del cicloalquenilalquilo está independientemente sin sustituir o sustituido con 1, 2, 3, 4 ó 5 sustituyentes, en la que los sustituyentes opcionales se seleccionan entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, ciano, oxo, metilenodioxi, etilenodioxi, -G1, -NO2, -OR1a, -OC (O) R1a, -OC (O) N (Rb) (R3a), -SR1a, -S (O) 2R2a, S (O) 2N (Rb) (R3a), -C (O) Ra, -C (O) OR1a, -C (O) N (Rb) (R3a), -N (Rb) (R3a), -N (Ra) C (O) R1a, -N (Ra) S (O) 2R2a, N (Ra) C (O) O (R1a), -N (Ra) C (O) N (Rb) (R3a), - (CR4aR5a) m-NO2, - (CR4aR5a) m-OR1a, - (CR4aR5a) m-OC (O) R1a, (CR4aR5a) m-OC (O) N (Rb) (R3a), - (CR4aR5a) m-SR1a, - (CR4aR5a) m-S (O) 2R2a, - (CR4aR5a) m-S (O) 2N (Rb) (R3a), (CR4aR5a) m-C (O) R1a, - (CR4aR5a) m-C (O) OR1a, - (CR4aR5a) m-C (O) N (Rb) (R3a), - (CR4aR5a) m-N (Rb) (R3a), (CR4aR5a) m-N (Ra) C (O) R1a, - (CR4aR5a) m-N (Ra) S (O) 2R2a, - (CR4aR5a) m-N (Ra) C (O) O (R1a), - (CR4aR5a) mN (Ra) C (O) N (Rb) (R3a), - (CR4aR5a) m-G1, cianoalquilo y haloalquilo; en la que cada uno de R1a y R3a, en cada caso, es independientemente hidrógeno, alquilo, haloalquilo, G1, o - (CR6R7) n-G1; R2a, en cada caso, es independientemente alquilo, haloalquilo, G1, o - (CR6R7) n-G1; cada uno de R4a, R5a, R6, y R7, en cada caso, es independientemente hidrógeno, halógeno, alquilo, o haloalquilo; cada uno de Ra y Rb, en cada caso, es independientemente hidrógeno, alquilo, o haloalquilo; cada uno de m y n, en cada caso, es independientemente 1, 2, 3, 4 ó 5; G1 es arilo, heteroarilo, heterociclo, cicloalquilo, o cicloalquenilo, en la que cada G1 está independientemente sin sustituir o sustituido con 1, 2, 3, 4 ó 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, ciano, oxo, metilenodioxi, etilenodioxi, -NO2, -OR1b, -OC (O) R1b, OC (O) N (Rb) (R3b), -SR1b, -S (O) 2R2b, -S (O) 2N (Rb) (R3b), -C (O) R1b, -C (O) OR1b, -C (O) N (Rb) (R3b), -N (Rb) (R3b), N (Ra) C (O) R1b, -N (Ra) S (O) 2R2b, -N (Ra) C (O) O (R1b), -N (Ra) C (O) N (Rb) (R3b), - (CR4bR5b) m-NO2, - (CR4bR5b) m-OR1b, - (CR4bR5b) m-OC (O) R1b, - (CR4bR5b) m-OC (O) N (Rb) (R3b), - (CR4bR5b) m-SR1b, - (CR4bR5b) m-S (O) 2R2b, - (CR4bR5b) mS (O) 2N (Rb) (R3b), - (CR4bR5b) m-C (O) R1b, - (CR4bR5b) m-C (O) OR1b, - (CR4bR5b) m-C (O) N (Rb) (R3b), - (CR4bR5b) mN (Rb) (R3b), - (CR4bR5b) m-N (Ra) C (O) R1b, - (CR4bR5b) m-N (Ra) S (O) 2R2b, - (CR4bR5b) m-N (Ra) C (O) O (R1b), - (CR4bR5b) m N (Ra) C (O) N (Rb) (R3b), cianoalquilo y haloalquilo; cada uno de R1b y R3b, en cada caso, es independientemente hidrógeno, alquilo, o haloalquilo; R2b, en cada caso, es independientemente alquilo o haloalquilo; cada uno de R4b y R5b, en cada caso, es independientemente hidrógeno, halógeno, alquilo, o haloalquilo; y Y2 es hidrógeno o alquilo, o una sal farmacéuticamente aceptable de los mismos.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式